Supplementary Appendix

Save this PDF as:

Size: px
Start display at page:

Download "Supplementary Appendix"

Transcription

1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373: DOI: /NEJMoa (PDF updated June 30, 2016.)

2 Supplementary Appendix Trial Organization Page 2 Endpoint Definitions Page 10 Figure S1. Forest Plot of All Prespecified Subgroup Analyses for the Primary Page 11 Composite Cardiovascular Outcome Table S1. Baseline Characteristics of the Trial Participants, According Page 14 to Assigned Study Medication Table S2. Initiation of Chronic Insulin Therapy or Additional Antihyperglycemic Agents Page 16 in the Sitagliptin and Placebo Groups Table S3. Cardiovascular Outcomes: Per Protocol Page 17 Table S4. Acute Pancreatitis Page 18 Table S5. Additional Clinical Events of Interest Page 19 1

3 Trial Organization Principal Investigators Rury R. Holman, Diabetes Trials Unit, University of Oxford, Oxford, UK Eric D. Peterson, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC Executive Committee Rury R. Holman (Joint-chair), Diabetes Trials Unit, University of Oxford, Oxford, UK Eric D. Peterson (Joint-chair), Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC Paul W. Armstrong, University of Alberta, Alberta, Edmonton, Canada John B. Buse, University of North Carolina at Chapel Hill, Chapel Hill, NC Robert G. Josse, University of Toronto, Toronto, Ontario Canada Keith D. Kaufman, Merck, Kenilworth, NJ Joerg Koglin, Merck, Kenilworth, NJ Scott Korn, Merck, Kenilworth, NJ John M. Lachin, George Washington University Biostatistics Center, Rockville, MD Darren K. McGuire, University of Texas-Southwestern Medical Center, Dallas, TX Eberhard Standl, Munich Diabetes Research Institute, Munich, Germany Peter P. Stein, Merck, Kenilworth, NJ Shailaja Suryawanshi, Merck, Kenilworth, NJ Frans Van de Werf, University of Leuven, Belgium Observer Samuel S. Engel, Merck, Kenilworth, NJ Former Members Robert M. Califf, formerly of the Duke Translational Medicine Institute, Duke University School of Medicine, Durham, NC Barry J. Goldstein, formerly of Merck, Kenilworth, NJ Deborah R. Shapiro, formerly of Merck, Kenilworth, NJ Robert Silverman, formerly of Merck, Kenilworth, NJ DCRI & DTU Clinical Leads, Study Team, and Key Statisticians Clinical Leads Angelyn Bethel, Diabetes Trials Unit, University of Oxford, Oxford, UK Jennifer Green, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC Study Team DCRI Operations: Sarah Hayden, Karen Hannan, Kirby Quintero, Tyrus Rorick, Lisa Berdan, Dianne Leloudis, Sharon Califf CEC: Matt Wilson, Diana McFarron Safety: Kathleen Trollinger, Jean Pesarchick Data Management: Lisa Eskenazi, Curtis Campbell, Owen Townes, Debra Tolsma 2

4 DTU Operations: Joanne Keenan, Joanne Milton, Rajbir Athwal, Julie Darbyshire, Zoë Doran Informatics: Ian Kennedy, Vanessa Gregory Key Statisticians DCRI Jyotsna Garg, Yuliya Lokhnygina, Kristi Prather, Anne Wolfley DTU Muhammed Usman, Abdelouahid Tajjar, Richard Gray Data Safety and Monitoring Committee Marc A. Pfeffer (chair), Brigham and Women's Hospital, Boston, MA Hertzel C. Gerstein, McMaster University, Hamilton, Ontario, Canada Leif Groop, Lund University, Lund, Sweden John J. McMurray, University of Glasgow, Glasgow, Scotland Stuart J. Pocock, London School of Hygiene and Tropical Medicine, London, England Observer Tim Clayton (independent statistician), London School of Hygiene and Tropical Medicine, London, UK Operations Committee Isaac Sinay, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina David Brieger, Concord Hospital, Concord, New South Wales, Australia Stephen Stranks, Southern Adelaide Diabetes and Endocrine Services, Southern Adelaide, Australia Andre Scheen, University of Liège, Liège, Belgium Renato Lopes, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, and Federal University of São Paulo, Paulista School of Medicine, São Paulo, Brazil Tsvetalina Tankova, University Specialized Hospital for Active Treatment in Endocrinology, Medical University, Sofia, Bulgaria Irene Hramiak, St. Joseph's Health Care London, London, Ontario, Canada Carlos Raffo Grado, Centre Region CINVEC, Viña del Mar, Chile Yang Wenying, China-Japan Friendship Hospital, Beijing, China Junbo Ge, Zhongshan Hospital Fudan University, Shanghai, China Pablo Aschner, Javeriana University School of Medicine, Bogota, Colombia Jan Skrha, Charles University, Prague, Czech Republic Anu Ambos, North Estonia Medical Centre, Tallinn, Estonia Timo Strandberg, Universities of Helsinki and Oulu, Geriatrics, and Helsinki University Central Hospital, Helsinki, Finland Florence Travert, Hôpital Bichat-Claude Bernard, Paris, France Markolf Hanefeld, GWT Technical University, Dresden, Germany Axel Riefflin, Gemeinschaftspraxis Husby, Husby, Germany Juliana C.N. Chan, The Chinese University of Hong Kong, Shatin, Hong Kong Peter Ofner, Gottsegen Gyorgy Hungarian Institute of Cardiology, Budapest, Hungary 3

5 N.K. Reddy, CARE Hospital, Clinical Research Department, Hyderabad, India Johann Christopher, CARE Hospital, Clinical Research Department, Hyderabad, India Atul Mathur, Fortis Escorts Heart Institute & Research Center, New Delhi, India Priyadarshini Arambam, Fortis Escorts Heart Institute & Research Center, New Delhi, India Sanjay Mittal, Medanta The Medicity, Gurgaon (Haryana), India Mukul Manchanda, Medanta The Medicity, Gurgaon (Haryana), India Julio Wainstein, The E. Wolfson Medical Center, Holon, Israel Giuseppe Ambrosio, University of Perugia School of Medicine, Perugia, Italy Valdis Pirags, Pauls Stradins Clinical University Hospital, Latvian University, Riga, Latvia Neli Jakuboniene, Lithuanian University of Health Sciences Hospital, Kaunas, Lithuania Mafauzy Mohamed, University Sains Malaysia Health Campus, Kelantan, Malaysia Russell Scott, Christchurch Hospital, Christchurch, New Zealand Harvey White, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand Jan Cornel, Medical Center Alkmaar, Alkmaar, Netherlands Sigrun Halvorsen, Oslo University, Oslo, Norway A. Tykarski, University School of Medical Sciences, Poznań, Poland Ioan Andrei Veresiu, Emergency County Hospital, Cluj-Napoca, Romania Alexander V. Dreval, Moscow Regional Scientific Research Clinical Institute, Moscow, Russia Inna Misinkova, Moscow Regional Scientific Research Clinical Institute, Moscow, Russia E. Shyong Tai, Yong Loo Lin School of Medicine, Singapore Boris Krahulec, Comenius University School of Medicine Hospital, Bratislava, Slovakia Larry Distiller, Centre for Diabetes and Endocrinology, Johannesburg, South Africa Yongsoo Park, Hanyan University Guri Hospital, Seoul, South Korea Adela Rovira, Fundacion Jimenez Diaz, Polyclinic Endocrinology, Madrid, Spain Michael Alversson, Karolinska University Hospital, Solna, Stockholm, Sweden Lee-Ming Chuang, National Taiwan University Hospital, Taipei, Taiwan Tuncay Delibasi, DIŞKAPI Ankara Yildirim Beyazit Education Research Hospital Clinic of Internal Medicine, Ankara, Turkey Amanda Adler, Wolfson Diabetes & Endocrine Clinic, Cambridge University Hospitals Foundation Trust, Addenbrooke's Hospital, Cambridge, England Helena Wachslicht Rodbard, Endocrine and Metabolic Consultants, Rockville, MD Michel Marre, The Diabetes Association of Vascular Risk Hospital Group, Paris, France David Goff, Wake Forest University School of Medicine, Winston-Salem, NC Antonio Chacra, Federal University of São Paulo, Paulista School of Medicine, São Paulo, Brazil Clinical Events Adjudication Committee Duke Clinical Research Institute: Adam DeVore, Anne Beaven, Bimal Shah, Bradford Hirsch, Bryan Batch, Cheryl Bushnell, Chet Patel, Chiara Melloni, Christine Henshaw, David Kong, Diana McFarron, Gwen Bernecki, Hans Tillman, Hyun Jae Kang, Jennifer Green, Jodi Hawes, John Strickler, Jonathan Piccini, Julian Wilder, Karen Alexander, Kenneth Mahaffey, Keyur Patel, Kristen Hyland, Kristen Newby, Larry Jackson, Lauren Cooper, Luciana Armaganijan, Lynda Szczeh, Massaya Koshizaka, Matthew Roe, Michael Morse, Patricia Guimaraes, Paul Hess, Pierluigi Tricoci, Rajendra Mehta, Renato Lopes, Rob Mathews, 4

6 Robb Kociol, Robert Harrison, Robert Mentz, Sean Pokorney, Thomas Leblanc, Valentina Lazzarini, Zubin Eapen Brazilian Clinical Research Institute: Adriano Truffa, Emil Fosbol, Flavio Brito, Marcelo Katz, M. Cecilia Bahit, Marilia Santos, Pedro Barros, Sabrina Bernardez Site Investigators Argentina Andres Francisco Alvarisqueta, Pablo Arias, Ana Lía Cagide, Pedro Rosario Fabián Calella, Maria Cecilia Cantero, Juan Pablo Cimbaro Canella, Marcela Andrea Cipullo, Luis de Loredo, Elizabeth Silvana Gelersztein, Silvia Beatriz Gorban de Lapertosa, Maria Isabel del Valle Klyver, Laura Elena Maffei, Natacha Maldonado, Alejandra Isabel Oviedo, Daniel Leonardo Piskorz, Maria Carolina Ridruejo, Silvia Salomé Saavedra, Horacio Angel Sessa, Isaac Rubén Sinay, Georgina Daniela Sposetti, Maria Rosa Ulla, Marisa Liliana Vico, Jorge Norberto Waitman Australia Maurits Binnekamp, Patrick Carroll, Wah Cheung, Peter Colman, Tim Davis, Ferdinandus De Looze, Michael demden, Greg Fulcher, Murray Gerstman, Andrew Hamilton, Sam Lehman, Robert Moses, Joe Proietto, Adam Roberts, Jonathan Shaw, Richard Simpson, Ashim Sinha, Steve Stranks, Yong Tan, Duncan Topliss, Parind Vora, Jonathon Waites Belgium Laurent Crenier, Olivier Descamps, Bart Keymeulen, Chantal Mathieu, Frank Nobels, André Scheen, Annick Van den Bruel, Luc Van Gaal Brazil João Lindolfo Cunha Borges, Adriana Costa e Forti, Freddy Goldberg Eliaschewitz, João Soares Felício, Luiz Henrique Maciel Griz, Miguel Nasser Hissa, Silmara Leite, Daniel Panarotto, Pedro Pimentel Filho, Nelson Rassi, Jose Kerr Saraiva, José Augusto Sgarbi, Ricardo Pereira Silva, Marcos Tambascia, Dalisbor Marcelo Weber Silva Bulgaria Roza Bobeva, Rumena Bostandzhieva, Ivan Cinlikov, Mariana Georgieva, Dimitar Iliev, Elena Ilieva, Snejina Kovacheva, Liudmila Liubenova, Zahari Nikitov, Galina SHeinikova, Antoanela Slavcheva, Vesela Spasova, Tsvetalina Tankova, Theodora Temelkova-Kurktschiev, Damyanova Velichka, Andrian Yakov Canada Andre Carpentier, Jean-Louis Chiasson, Christian Constance, Richard Dumas, Pierre Filteau, Claude Garceau, Irene Hramiak, Thao Huynh, Stephanie Kaiser, Jan Kornder, Lawrence Leiter, Laurie Mereu, David Miller, Shekhar Pandey, Zubin Punthakee, Remi Rabasa-Lhoret, Yves Robitaille, Kevin Saunders, Ronald Sigal, John Sigalas, Saul Vizel, Stanley Weisnagel, Vincent Woo, Jean-Francois Yale, Kibar Yared, Bernard Zinman Chile Lia Bernardita Bunster Balocchi, Edgardo Enrique Escobar Cerda, Eduardo Enrique Garces Flores, Fernando Tomás Lanas Zanetti, Andrea del Pilar Larrazabal Miranda, José Manuel Morales Alvarado, Claudia Monica Olivares Cañon, Sergio Hernán Potthoff Cárdenas, Carlos Antonio Raffo Grado, Manuel Eduardo Rodriguez Venegas, Victor Areli Saavedra Gajardo, Bernhard Henoc Westerberg Maldonado 5

7 China Lu Lu Chen, Jixiang Dong, Xiaohui Guo, Quan-Min Li, BingYin SHI, Xu Lei Tang, Tao Yang, Wen-Ying Yang, Shao Xiong Zheng Colombia Pablo Aschner Montoya, Rodrigo Botero Lopez, Julian Alonso Coronel Arroyo, Carlos Alberto Cure, Ana Maria Gómez Medina, Dora Inés Molina, German Anibal Perez Amador, Alberto Reyes Rincon, Miguel Alberto Urina Triana, Alex Valenzuela Rincon, Sebastián Vélez Pelaez, Hernán Yupanqui Lozno Czech Republic Tomas Brabec, Tomas Brychta, Jitka Hasalova Zapletalova, Jana Havelkova, Katerina Hejnicova, Olga Hola, Marie Hornackova, Tomas Hrdina, Dana Kafkova, Ivana Kellnerova, Tomas Krystl, Vlasta Kutejova, Iva Mikulkova, Jana Nevrla, C Pantlikova, Martin Petr, Eva Racicka, Renata Sarbochova, Jan Skrha, Katerina Smolenakova, Rene Turcinek, Katerina Urbancova, Jirina Vejvodova, Michaela Vondrakova, Richard Zachoval Estonia Ingrid Alt, Anu Ambos, Ülle Kaasik, Kaia Kiiroja, Riin Lanno, Kaja Märtsin, Marju Past, Hella Vides, Liina Viitas Finland Ilkka Kantola, Sakari Nieminen, Merja Perhonen, Jorma Strand, Timo Strandberg, Timo Valle France Annie Clergeot, Thierry Couffinhal, Jean-Pierre Courreges, Didier Gouet, Philippe Moulin, Florence Travert, Olivier Ziegler Germany Klaus Badenhoop, Thomas Behnke, Gwendolyn Bender, Martin Braun, Janna Dshabrailov, Andreas Hamann, Markolf Hanefeld, Agnes Himpel-Boenninghoff, Wolfram Kamke, Christian Kasperk, Joerg Luedemann, Peter Mayr, Martin Merkel, Erika-Maria Oerter, Marc-Alexander Ohlow, Petra Ott, Ulrich Overhoff, Björn Paschen, Rudolf Remppis, Axel Riefflin, Ludger Rose, Petra-Maria Schumm-Draeger, Thomas Segiet, Hermann-Josef Strotmann, Gerhard Stuchlik, Werner Stürmer, Manuela Thinesse- Mallwitz, Andrea Tytko, Ulrich Wendisch, Jurgen Wurziger Hong Kong Andrew Yiu-Yan Ho, Grace Kam, Alice Pik Shan Kong, Yat Yin Lam, Emmy Yuen-Fun Lau, Stephen Lee, Shing-Chung Siu, Brian Tomlinson, Chiu-Chi Tsang, Vincent Tok-Fai Yeung Hungary Enikő Dezső, Mihály Dudás, Irén Földesi, Tibor Fülöp, Nóra Késmárki, Laszlo Koranyi, Karoly Nagy, Peter Ofner, Tamás Oroszlán, Zsolt Pécsvárady, Zsolt Ples, András Taller India Pankaj Agarwal, Sunil Ambulkar, Sosale Aravind, Vijayam Balaji, Johann Christopher, Sanjay Kalra, Jothydev Kesavadev, Harshada Kudalkar, Ajay Kumar, Anoop Misra, Ambrish Mithal, Viswanathan Mohan, Shailesh Pitale, Muthu Ramu, Naveen Reddy, Sanjiv Shah, Paramesh Shamanna, A. Sharda, Ashok Sharma, Minakshisundharam Shunmugavelu, Shamanna Srikanta, Gulla Suryaprakash 6

8 Israel Galina Abramov, Faiad Adawi, Amir Bashkin, Mahmud Darawsha, Shmuel Fuchs, Ilana Harman-Boehm, Tonny Hayek, Anat Jaffe, Hila Knobler, Oscar Minuchin, Morris Mosseri, Michael Shechter, Ilan Shimon, Naftali Stern, Anat Tsur, Victor Vishlitzky, Julio Wainstein Italy Francesca Alfonsi, Franco Cavalot, Lucia Del Vecchio, Anna Frisinghelli, Sergio Gambardella, Davide Lauro, Giuseppe Lembo, Sergio Leotta, Sergio Mondillo, Salvatore Novo, Roberto Pedrinelli, Piermarco Piatti, Alessandro Salvioni, Isabella Tritto, Donatella Zavaroni Zavaroni Korea, Republic of Kyu Jeung Ahn, Kyung Mook Choi, ChoonHee Chung, Seung Jin Han, Doo-Man Kim, In Joo Kim, Moo Hyun Kim, In Kyu Lee, Moonsuk Nam, Ie Byung Park, Kang Seo Park, Tae Sun Park, YongSoo Park, Eun Jung Rhee, Soon-Jib Yoo Latvia Ilze Andersone, Astra Balode, Ruta Eglite, Arcils Gersamija, Natalja Kakurina, Baiba Jegere, Inta Leitane, Sigita Pastare, Valdis Pirags, Valda Stalte, Dace Teterovska Lithuania Kristina Baltramonaitiene, Lina Barsiene, Jonas Ceponis, Neli Jakuboniene, Jurate Lasiene, Andrej Levinger, Ausra Sirutaviciene, Marijona Sulskiene, Liuda Urbanaviciene, Leonas Valius, Egle Varanauskiene, Dzilda Velickiene Malaysia Kauthaman A. Mahendran, Muhammad Radzi Abu Hassan, Nor Azizah Aziz, Zanariah Hussein, Ikram Shah Ismail, Nor Azmi Kamaruddin, Mafauzy Mohamed, Zawawi Nordin, Sree Kantan Nayar P.K.S. Nayar, G.R. Letchuman Ramanathan, Radhakrishna Sothiratnam Netherlands Hugo Beijerbacht, Rob Breedveld, J.H. Cornel, Frank Den Hartog, Walter Hermans, Bas Kietselaer, Adriaan Kooy, Timo Lenderink, Pieter Nierop, Jaap Remmen, Gloria Rojas Lingan, Eelko Ronner, Robert Van der Heijden, Maarten Van Hessen, Wouter van Kempen, Christine Voors-Pette, Iris Westendorp New Zealand John Baker, Jocelyne Benatar, Richard Cutfield, Jeremy Krebs, Robert Leikis, Helen Lunt, Patrick Manning, Russell Scott, Mike Williams Norway Kåre Birkeland, Tor Claudi, Sigrun Halvorsen, Helge Istad, Thomas Karlsson, Jørn Ossum Gronert Poland Malgorzata Arciszewska, Edyta Artemiuk, Elzbieta Blach, Tomasz Blicharski, Katarzyna Cypryk, Magda Dabrowska, Grzegorz Górny, Maria Górska, Iwona Jakubowska, Ewa Jazwinska-Tarnawska, Agnieszka Karczmarczyk, Jolanta Kitowska-Koterla, Lukasz Koltowski, Ewa Krzyzagorska, Dariusz Pasternak, Jolanta Pentela-Nowicka, Wojciech Piesiewicz, Magdalena Przekwas-Jaruchowska, Marek Rajzer, Anna Salamon- Ferenc, Andrzej Sawicki, Tadeusz Skowron, Adam Śmiałowski, Andrzej Tykarski 7

9 Romania Adrian Albota, Carmina Alexandru, Carmen Crisan, Adriana Dumitrescu, Ioana Emilia Ferariu, Delia- Adriana Lupusoru, Mircea Munteanu, Doru Negru, Alina Nicolau, Ella Pintiliei, Alexandrina Popescu, Gabriela SERBAN, Ioan Andrei Veresiu, Mihaela VOITEC Russian Federation Alina Babenko, Olga Barbarash, Irina Bondar, Petr Chizhov, Alexander Demin, Svetlana Dora, Alexander Dreval, Olga Ershova, Nikolay Gratsiansky, Galina Ketova, Mikhail Kotelnikov, Sergey Levashov, Tatiana Morugova, Sveltana Mustafina, Stanislav Pekarskiy, Tatiana Raskina, Elena Rechkova, Yulia Samoylova, Olga Sazonova, Alexander Sherenkov, Natalia Shilkina, Olga Stetsyuk, Tatiana Tretyakova, Elena Turova, Farida Valeeva, Vladimir Zadionchenko Singapore Rinkoo Dalan, Ru San Tan, Leslie Tay Slovakia Ingrid Buganova, Jaroslav Fabry, CULAK Jan, Boris Krahulec, Eva Toserova, Roman Zak, Jana Zimanova South Africa Ayesha Badat, Frederik Bester, Lesley Burgess, Douwe De Jong, Larry Distiller, Graham Ellis, Leon Fouche, Prabashini Govender, Uttam Govind, Visvakuren Naidoo, Grant Nieuwoudt, Hendrik Nortje, Paul Rheeder, Leslie Robertson, Naeem Siddique, Anne-Marie Stapelberg, Yvonne Trinder, Andie Van Der Merwe, Louie Van Zyl, Marianne Viljoen, Agatha Wilhase Spain Marta Botella, Fernando Civeira Murillo, Luis de Teresa, Francisco Javier Del Cañizo, Blas Gil Extremera, Esteban Jodar Gimeno, Alberto Martin-Hidalgo, Cristóbal Morales, Andreu Nubiola, Adela Rovira, Francisco Tinahones Madueño, Salvador Tranche, Carlos Trescolí Serrano Sweden Michael Alvarsson, Enrique Eizyk, Anders Gillblad, Petter Johansson, Magnus Löndahl, Åke Ohlsson- Önerud, Aslak Rautio, Ulf Sundström, Ingemar Torstensson Taiwan Jung-Fu Chen, Chien-Wen Chou, Lee-Ming Chuang, Low-Tone Ho, I-Chang Hsieh, Bien-Hsien Huang, Chen-Ling Huang, Chien-Ning Huang, Wen-Ter Lai, Ping-Han Lo, Dee Pei, Wayne Huey-Herng Sheu, Shu- Yi Wang Turkey Mustafa Araz, Okan Bakiner, Abdurrahman Comlekci, Tuncay Delibasi, Serdar Guler, Ibrahim Sahin, Fulden Sarac, Ilhan Tarkun, Kubilay Ukinc, Murat Yilmaz United Kingdom Essam Abdulhakim, Prakash Abraham, Karen Adamson, Amanda Adler, Mark Blagden, Charles Bundy, Mark Daly, Melanie Davies, Mayura Deshpande, Sharon Gillings, Peter Harvey, Veronika Horvathova, Veronika Horvathova, Dani Hristova, Alan Jaap, Andrew Johnson, Hugh Jones, Jerome Kerrane, Anne Kilvert, Tomas Ko, Jesse Kumar, Robert Lindsay, Jennifer Litchfield, Rory McCrimmon, John McKnight, Beverley, Ann Millward, Babatunde Oyesile, Tejpal Purewal, Chinnusamy Ravikumar, Anthony Robinson, 8

10 Thozhukat Sathyapalan, Hamish Simpson, Hawys Thomas, Wayne Turner, Jola Weaver, John Wilding, Philip Wiles United States Kevin Adkins, Basil Akpunonu, Jeanine Albu, George Anagnostis, Lawrence Anastasi, Georges Argoud, Vanita Aroda, Masoud Azizad, Mary Ann Banerji, Anthony Bartkowiak Jr, Harold Bays, Phillip Behn, Richard Bergenstal, Anuj Bhargava, Donald Bias, Eric Bolster, Patricia Buchanan, Robert Busch, Chhavi Chadha, Mark Chang, Cynthia Cheng, Alan Cohen, Joshua Cohen, Bertrand Cole, Lisa Connery, Michael Cooperman, William Cushman, Ronald DAgostino, Mark Davies, Priya Dayamani, James De Lemos, Mario De Meireles, Julius Dean, Drake DeHart, Robert Detweiler, Daniel Donovan, Pamela Dugano-Daphnis, Michael Dulin, Fredrick Dunn, Charles Eaton, Bernard Erickson, Roger Estevez, Mark Feinglos, Vivian Fonseca, Rex Force, Alan Forker, Donald Fox, John Gabriel, Ronald Garcia, Tim Garvey, Linda Gaudiani, Asqual Getaneh, David Goff, Anne Goldberg, Steven Goldman, Kristen Hairston, Roy Harris, W. Herbert Haught, Horacio Hidalgo Jr, Alexander Higgins, Vonda Houchin, Rodney Ison, Glenn Jacobs, Naseem Jaffrani, Behjath Jafry, Patricia Kapsner, William Kaye, Ajay Labroo, Lawrence Levinson, Stephen Lewis, Michael Lillestol, Louis Luttrell, Ivy Madu, Robert McNeill, Bryan Merrick, Frank Metzger, Venkatesh Nadar, Steven Nagelberg, Stephen Nash, Suzanne Oparil, Kwame Osei, Vasilios Papademetriou, Naynesh Patel, Carolyn Pedley, Adrienne Prentiss, Mark Radbill, Ajit Raisinghani, Negah Rassouli, Rajneesh Reddy, Peter Rees, Marc Rendell, David Robbins, Helena Rodbard, Jane Rohlf, Hal Roseman, Lance Rudolph, Laurie Sadler, Adrian Schnall, Rashmi Schramm, Ulrich Schubart, Tara Seneviratne, Michael Shanik, Harvey Snyder, Chris Sorli, Mark Stich, Mary Ellen Sweeney, John Tsao, Philomena Ukwade, Dilip Viswanath, Anthony Vo, Craig Vogel, Stephen Voyce, Howard Weintraub, Judith White, Mark Wood, Patricia Wu, Carol Wysham, Robert Zimmerman 9

11 Endpoint Definitions Primary Efficacy Endpoint Time to first confirmed CV event in the primary composite CV endpoint: defined as the time from randomization to first confirmed event in the primary composite CV endpoint (CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization). Secondary Efficacy Endpoints Time to first confirmed CV event in the secondary composite CV endpoint: defined as time from randomization to first confirmed event in the secondary composite CV endpoint (CVrelated death, nonfatal MI, or nonfatal stroke). Time to first confirmed CV event for individual CV endpoints: defined as time from randomization to each of the components of the primary composite endpoint (CV-related death, MI [fatal + nonfatal], stroke [fatal +nonfatal], and unstable angina requiring hospitalization). Time to all-cause mortality: defined as time from randomization to death due to any cause. Time to congestive heart failure: defined as time from randomization to hospital admission for congestive heart failure and treatment with intravenous diuretics, inotropes, or vasodilator therapy. Change from baseline in urinary albumin to creatinine ratio over time. Change from baseline in egfr over time. Change from baseline in HbA1c over time. Time to initiation of chronic insulin therapy: defined as continuous use longer than three months in patients not receiving insulin at baseline. Time to initiation of first co-interventional agent (i.e., next oral AHA or chronic insulin therapy in patients not receiving insulin at baseline) Count of hospitalizations for any reason. Exploratory Efficacy Endpoints Time to non-cv death: defined as time from randomization to non-cv death Time to revascularization procedure: defined as time from randomization to time of first cardiovascular or peripheral revascularization procedure (applicable procedures to be listed in the clinical events list of the ecrf) Change from baseline in weight over time Counts of severe hypoglycemia 10

12 Figure S1. Forest Plot of All Prespecified Subgroup Analyses for the Primary Composite Cardiovascular Outcome. 11

13 12

14 13

15 Table S1. Baseline Characteristics of the Trial Participants, According to Assigned Study Medication.* Characteristic All N=14,671 Sitagliptin N=7332 Placebo N=7339 Age (years) 65.5 ± ± ± 8.0 Female sex 4297 (29.3%) 2134 (29.1%) 2163 (29.5%) Race/Ethnicity White 9957 (67.9%) 4955 (67.6%) 5002 (68.2%) Black 447 (3.0%) 206 (2.8%) 241 (3.3%) Asian 3265 (22.3%) 1654 (22.6%) 1611 (22.0%) Other 1002 (6.8%) 517 (7.1%) 485 (6.6%) Hispanic or Latino 1798 (12.3%) 886 (12.1%) 912 (12.4%) Duration of diabetes (years) Mean 11.6 ± ± ± 8.1 Qualifying HbA 1c (%) Mean 7.2 ± ± ± 0.5 Body mass index (kg/m 2 ) 30.2 ± ± ± 5.7 Systolic blood pressure (mmhg) 135 ± ± ± 17.1 Diastolic blood pressure (mmhg) 77.2 ± ± ± 10.6 egfr (ml/min/1.73 m 2 ) 74.9 ± ± ± 20.9 egfr <50 ml/min/1.73 m (9.4%) 686 (9.5%) 683 (9.4%) Urinary albumin:creatinine ratio (mg/g) Median 10.6 (3.5, 35.5) 10.3 (3.5, 34.6) 11.4 (3.6, 36.2) Total cholesterol (mg/dl) ± ± ± 45.9 LDL cholesterol (mg/dl) 91.0 ± ± ± 51.2 HDL cholesterol (mg/dl) 43.5 ± ± ± 13.0 Triglycerides (mg/dl) ± ± ± 98.8 Prior cardiovascular disease (74.0%) 5397 (73.6%) 5466 (74.5%) Myocardial infarction 6255 (42.6%) 3133 (42.7%) 3122 (42.5%) >50% coronary stenosis 7687 (52.4%) 3804 (51.9%) 3883 (52.9%) Prior PCI 5714 (39.5%) 2814 (38.9%) 2900 (40.1%) CABG 3664 (25.0%) 1845 (25.2%) 1819 (24.8%) Prior cerebrovascular disease 3588 (24.5%) 1806 (24.6%) 1782 (24.3%) Prior Peripheral arterial disease 2433 (16.6%) 1217 (16.6%) 1216 (16.6%) Prior Congestive heart failure 2643 (18.0%) 1303 (17.8%) 1340 (18.3%) NYHA class 3 or higher 373 (2.5%) 171 (2.3%) 202 (2.8%) Cigarette smoking Never smoked 7149 (48.7%) 3583 (48.9%) 3566 (48.6%) Prior smoker 5844 (39.8%) 2884 (39.3%) 2960 (40.3%) Current smoker 1678 (11.4%) 865 (11.8%) 813 (11.1%) 14

16 Characteristic Medication use Antihyperglycemic All N=14,671 Sitagliptin N=7332 Placebo N=7339 Metformin 11,966 (81.6%) 5936 (81.0%) 6030 (82.2%) Sulfonylurea 6645 (45.3%) 3346 (45.6%) 3299 (45.0%) Thiazolidinedione 396 (2.7%) 196 (2.7%) 200 (2.7%) Insulin 3408 (23.2%) 1724 (23.5%) 1684 (22.9%) Antihypertensive Antiplatelet Lipid lowering Beta blocker 9322 (63.5%) 4647 (63.4%) 4675 (63.7%) ACE inhibitor or ARB 11,555 (78.8%) 5743 (78.3%) 5812 (79.2%) Calcium channel blocker 4961 (33.8%) 2444 (33.3%) 2517 (34.3%) Diuretic 6020 (41.0%) 2976 (40.6%) 3044 (41.5%) Aspirin 11,518 (78.5%) 5764 (78.6%) 5754 (78.4%) Other antiplatelet 3187 (21.7%) 1593 (21.7%) 1594 (21.7%) Statin 11,719 (79.9%) 5851 (79.8%) 5868 (80.0%) Ezetimibe 761 (5.2%) 386 (5.3%) 375 (5.1%) *Values shown are for the intention-to-treat population. Results for continuous variables are mean ± 1 SD or median (Q1, Q3) and categorical variables are n (%). ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, CABG coronary artery bypass graft, egfr estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, PCI percutaneous coronary intervention. Age missing among patients in Lithuania as birth date could not be provided. Duration = (year of randomization year of diagnosis) + 1. MDRD formula used to calculate egfr. Site-reported values are presented. Urinary albumin:creatinine ratio data available for only 5148 patients (n= 2606 for sitagliptin, n=2542 for placebo). Medications taken alone or in combination. SI conversion factors: urine albumin creatinine ratio (mg/g to g/mol), multiply by ; total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) (mg/dl to mmol/l), multiply by ; triglycerides (mg/dl to mmol/l), multiply by

17 Table S2. Initiation of Chronic Insulin Therapy or Additional Antihyperglycemic Agents in the Sitagliptin and Placebo Groups. Number of patients initiating chronic insulin therapy Sitagliptin N=7332 Event rate per 100 pt-years Cumulative incidence (%) of event 1 year, % (95% CI) 3.2 (2.77, 3.72) 4.8 (4.29, 5.43) 2 years, % (95% CI) 6.4 (5.75, 7.07) 9.7 (8.93, 10.53) 3 years, % (95% CI) 9.8 (8.96, 10.71) 14.1 (13.09, 15.12) 4 years, % (95% CI) 13.2 (12.09, 14.50) 17.5 (16.27, 18.89) Number of patients initiating additional antihyperglycemic agents Event rate per 100 pt-years Cumulative incidence (%) of event 1 year, % (95% CI) 6.7 (6.10, 7.27) 9.3 (8.64, 10.00) 2 years, % (95% CI) 14.9 (14.05, 15.74) 20.3 (19.38, 21.30) 3 years, % (95% CI) 23.4 (22.23, 24.52) 31.3 (30.05, 32.60) 4 years, % (95% CI) 33.1 (31.37, 34.91) 41.5 (39.62, 43.34) Placebo N=7339 HR (95% CI) P Value 542 / 5608 (9.7%) 744 / 5655 (13.2%) 0.70 ( ) < / 7332 (21.7%) 2046 / 7339 (27.9%) 0.72 ( ) <0.001 P values reported in this table are based on the Wald statistic from a Cox model stratified on region testing difference in hazards. 16

18 Table S3. Cardiovascular Outcomes: Per Protocol. Outcome Sitagliptin N=7257 Placebo N=7266 HR (95% CI) P Value Participants with Event n (%); Event Rate per 100 pt-years Participants with Event n (%); Event Rate per 100 pt-years Primary composite CV outcome: CV death, 695 (9.6%); (9.6%); ( ) <0.001* nonfatal MI, nonfatal stroke, hospitalization for unstable angina CV death 220 (3.0%) 199 (2.7%) Nonfatal MI 249 (3.4%) 250 (3.4%) Nonfatal stroke 129 (1.8%) 142 (2.0%) Hospitalization for unstable angina 97 (1.3%) 104 (1.4%) Secondary composite CV outcome: CV 609 (8.4%); (8.3%); ( ) <0.001* death, nonfatal MI, nonfatal stroke CV death 221 (3.0%) 201 (2.8%) Nonfatal MI 257 (3.5%) 257 (3.5%) Nonfatal stroke 131 (1.8%) 144 (2.0%) Secondary outcomes CV death 250 (3.4%); (3.2%); ( ) Fatal + nonfatal MI 269 (3.7%); (3.8%); ( ) Fatal + nonfatal stroke 157 (2.2%); (2.3%); ( ) Hospitalization for unstable angina 104 (1.4%); (1.6%); ( ) All-cause mortality 342 (4.7%); (4.3%); ( ) Hospitalization for HF 200 (2.8%); (2.8%); ( ) Composite of hospitalization for HF or CV death 415 (5.7%); (5.6%); ( ) *Noninferiority P value for a margin of 1.30 in hazard ratio. All other P values reported in this table are based on the Wald statistic from a Cox model stratified on region testing difference in hazards. CV denotes cardiovascular, HF heart failure, MI myocardial infarction. 17

19 Table S4. Acute Pancreatitis. Patients with Reported Event Reported Events Patients with Confirmed Event Confirmed Events Sitagliptin Placebo Sitagliptin Placebo Sitagliptin Placebo Sitagliptin Placebo Acute Pancreatitis Severe NA NA NA NA Mild NA NA NA NA Unknown Severity NA NA NA NA

20 Table S5. Additional Clinical Events of Interest. Event Sitagliptin N=7332 Placebo N=7339 Any diabetic complication None 4491 (64.1%) 4481 (64.3%) 1 complication 1740 (24.9%) 1719 (24.7%) 2 complications 528 (7.5%) 541 (7.8%) 3 complications 242 (3.5%) 227 (3.3%) Any hospitalization due to diabetes complications 233 (3.2%) 270 (3.7%) Hospitalization for hyperglycemia 74 (1.0%) 100 (1.4%) Diabetic eye disease 226 (3.1%) 180 (2.5%) Blindness due to diabetes 24 (0.3%) 25 (0.3) Retinopathy 205 (2.8%) 158 (2.2) Diabetic neuropathy 303 (4.1%) 281 (3.8%) Microalbuminuria 552 (7.8%) 553 (7.9%) Renal failure 100 (1.4%) 111 (1.5%) Peripheral vascular disease 232 (3.2%) 249 (3.4%) Peripheral arterial disease 197 (2.7%) 209 (2.9%) Amputation 60 (0.8%) 66 (0.9%) Gangrene 45 (0.6%) 52 (0.7%) Infections 1344 (18.4%) 1297 (17.7%) Gastrointestinal conditions 308 (4.2%) 302 (4.1%) Metabolic conditions 328 (4.5%) 326 (4.5%) Events in this table are predefined, prospectively collected events of interest expected to occur in participants with diabetes and are analyzed in the intention-to-treat population. Percentages presented for each event are for available data. Section 12.2 of the protocol (available online) gives further detail of the conditions comprising each category. 19

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content McGuire DK, Van de Werf F, Armstrong PW, et al; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart

More information

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective? FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Marc S. Sabatine, MD, MPH on behalf of the PEGASUS-TIMI 54 Executive

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and

More information

Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome

Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome Gregory G. Schwartz, MD PhD VA Medical Center and University of Colorado School of

More information

EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial

EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS

More information

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL

TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL Otavio Berwanger, MD, PhD - On behalf of the TREAT Trial Steering

More information

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,

More information

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of

More information

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,

More information

Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People

Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People November September 23, 20, 20102012 Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People Eva Lonn, Jackie Bosch, Jane Castelli, Andrea

More information

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes Original Article Effect of on Cardiovascular Outcomes in Type 2 Diabetes Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna

More information

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf

More information

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20

More information

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A

More information

Assistance Publique-Hopitaux de Paris, Hopital Bichat, Universite Paris 7 Denis Diderot, INSERM U-69, Paris, France 4

Assistance Publique-Hopitaux de Paris, Hopital Bichat, Universite Paris 7 Denis Diderot, INSERM U-69, Paris, France 4 The Late Consequences of Acute Coronary Syndromes: 2-Year Follow-up Outcomes, Procedures, and Treatment of Patients from the Global Registry of Acute Coronary Events (GRACE) S Goodman 1, W Huang 2, JM

More information

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes The new england journal of medicine Original Article Effect of on Cardiovascular Outcomes in Type 2 Diabetes Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D.,

More information

Prof. Renata Cífková, MD, CSc.

Prof. Renata Cífková, MD, CSc. Prof. Renata Cífková, MD, CSc. Head of the Department of Preventive Cardiology, Thomayer Teaching Hospital, Prague Focuses on arterial hypertension epidemiology, clinical trials, target organ damage prevention

More information

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative

More information

CASTLE HOWARD EVENT 2018

CASTLE HOWARD EVENT 2018 Castle Howard Triathlon Saturday 21st July 2018 Castle Howard Triathlon Sunday 22nd July 2018 The 'Brideshead Revisited' Sprint Plus - 800m/46km/8km Includes Macmillan Cancer Support Charity Place Race

More information

Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer

Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Patients Randomized by Country 187 UK n=187 Norway n=425 Finland

More information

An international, double-blind, phase III randomized trial. Main Results

An international, double-blind, phase III randomized trial. Main Results An international, double-blind, phase III randomized trial Main Results Robert Hart on behalf of the NAVIGATE ESUS Steering Committee and Investigators Sponsorship & Disclosures NAVIGATE ESUS was sponsored

More information

Expert Meeting on Large Simple Trials (LST s)

Expert Meeting on Large Simple Trials (LST s) Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes

More information

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Seung-Jung Park, MD, PhD On behalf of the BEST investigators Professor of Medicine, University of Ulsan College of

More information

Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM

Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM Efficacy by subgroup, and safety when LDL-C

More information

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.

More information

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental

More information

American Telemedicine Center, San Juan Health Center, Puerto Rico. Pradnet, Inc., Centro Especializado de Nutrición y Bariatría, Puerto Rico

American Telemedicine Center, San Juan Health Center, Puerto Rico. Pradnet, Inc., Centro Especializado de Nutrición y Bariatría, Puerto Rico List of Principal Investigators Investigator Name Colón, Dr. Gildred Ortíz-Carrasquillo, Dr. Ramón Figueroa Cruz, Dr. Wanda Arakaki, Dr. Richard Liljenquist, Dr. David Klaff, Dr. Leslie Wynne, Dr. Alan

More information

THE BRIDGE-ACS TRIAL

THE BRIDGE-ACS TRIAL A Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of Acute Coronary Syndromes: THE BRIDGE-ACS TRIAL Presenter: Otavio Berwanger (MD; PhD) on Behalf of the BRIDGE-ACS Steering

More information

SUPPLEMENTARY DATA American Diabetes Association. Published online at

SUPPLEMENTARY DATA American Diabetes Association. Published online at Participating investigators: Australia: Gary Wittert, Royal Adelaide Hospital, Adelaide; Greg Fulcher, Royal North Shore Hospital, St. Leonards. Guatemala: Luis-Alberto Ramirez-Roca, Clinica Las Americas;

More information

High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study

High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study DATA SUPPLEMENT High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study Anoop SV Shah, 1 Megan Griffiths, 1 Kuan Ken Lee, 1 David A McAllister,

More information

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,

More information

SEPI: Past, Present, and Future. Carol R. Glass The Catholic University of America Washington, DC, USA

SEPI: Past, Present, and Future. Carol R. Glass The Catholic University of America Washington, DC, USA SEPI: Past, Present, and Future Carol R. Glass The Catholic University of America Washington, DC, USA Carol s thoughts I m not a founding member but involved for almost 30 years will share some of my first

More information

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease Effects of Lowering LDL Cholesterol on Progression of Kidney Disease Richard Haynes, David Lewis, Jonathan Emberson, Christina Reith, Lawrence Agodoa, Alan Cass, Jonathan C. Craig, Dick de Zeeuw, Bo Feldt-Rasmussen,

More information

Name List of Scout of the Year

Name List of Scout of the Year Name List of Scout of the Year Name Sex Section Group Year of Award 1. Jimmy TONG Chun-kuen M Cub Scout 14 th Hong Kong Group 1987 2. YIP Chi-kwong M Scout 98 th Kowloon Group 1987 3. Wilfred MAK Wai-fung

More information

The Stabilization Of plaques using Darapladib (SOLID)-TIMI 52 trial: Primary Results

The Stabilization Of plaques using Darapladib (SOLID)-TIMI 52 trial: Primary Results The Stabilization Of plaques using Darapladib (SOLID)-TIMI 52 trial: Primary Results Michelle L. O Donoghue MD MPH, on behalf of the SOLID-TIMI 52 investigators European Society of Cardiology Congress

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. Brian A. Ference MD, MPhil, MSc, John J. P. Kastelein

More information

CONFIRMATION DOCKET REPORT- 4/4/2019 RONALD B. KING

CONFIRMATION DOCKET REPORT- 4/4/2019 RONALD B. KING 1950215 BUTTLES MONTOYA, CYNTHIA 1853063 CAIN EDWARDS, KURT W. & REBECCA 1950206 CAIN MACKEY, MICHAEL & REINA, MACKEY 1950209 CAIN MENDEZ, MARICELA RODARTE 1852885 CAIN PAEZ, DANIEL R. 3/25/19 san_report_mattercalendardocket

More information

Main Results Insulin Resistance Intervention after Stroke (IRIS) Trial

Main Results Insulin Resistance Intervention after Stroke (IRIS) Trial Main Results Insulin Resistance Intervention after Stroke (IRIS) Trial Walter N. Kernan, MD Professor of Medicine Yale School of Medicine February 17, 2016 Topic Presenter Disclosure Information Walter

More information

PALLAS. Dronedarone on Top of Standard Therapy. Stuart J. Connolly MD. on behalf of the PALLAS investigators

PALLAS. Dronedarone on Top of Standard Therapy. Stuart J. Connolly MD. on behalf of the PALLAS investigators PALLAS Permanent Atrial FibriLLAtion Outcome Study using on Top of Standard Therapy Stuart J. Connolly MD on behalf of the PALLAS investigators http://clinicaltrials.gov Number: NCT01151137 1 Disclosure

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative

More information

Name List of Scout of the Year

Name List of Scout of the Year Name List of Scout of the Year Name Sex Section Group Year of Award 1. Jimmy TONG Chun-kuen M Cub Scout 14 th Hong Kong Group 1987 2. YIP Chi-kwong M Scout 98 th Kowloon Group 1987 3. Wilfred MAK Wai-fung

More information

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2

More information

Count Down to COMBAT

Count Down to COMBAT Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University

More information

EUCLID Trial Primary Results Late Breaking Clinical Trial Presentation American Heart Association 2016 November 13 th 2016

EUCLID Trial Primary Results Late Breaking Clinical Trial Presentation American Heart Association 2016 November 13 th 2016 Manesh R. Patel, MD on behalf of the EUCLID Executive and Steering Committee and Investigators EUCLID Trial Primary Results Late Breaking Clinical Trial Presentation American Heart Association 2016 November

More information

AHA Nov 18, 2013 Late Breaking Session

AHA Nov 18, 2013 Late Breaking Session Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2013 Late Breaking Session Marc A. Pfeffer MD, PhD, on behalf of the TOPCAT Investigators TOPCAT

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2 Lipid Abnormalities Remain High among Treated Hypertensive Patients with Stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium Michel Guillaume 1, Eric Weber 2, Johan De Sutter

More information

Methods. Background and Objectives STRADIVARIUS

Methods. Background and Objectives STRADIVARIUS STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau

More information

PREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil

PREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil 11 PREVER STUDY What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs Professor at Universidade Federal of Rio Grande do Sul, Brazil Financial Support: PREVER investigators: Sandra C. FUCHS,

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Experiences with interim trial monitoring, particularly with early stopped trials

Experiences with interim trial monitoring, particularly with early stopped trials Experiences with interim trial monitoring, particularly with early stopped trials 1 Robert J Glynn, ScD Divisions of Preventive Medicine and Pharmacoepidemiology & Pharmacoeconomics, Brigham & Women s

More information

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division

More information

DECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.

DECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD. DECISION-CTO Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion Seung-Jung Park, MD., PhD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center,

More information

The Stabilization Of plaques using. Primary Results

The Stabilization Of plaques using. Primary Results The Stabilization Of plaques using Darapladib (SOLID)-TIMI 52 trial: Primary Results Michelle L. O Donoghue MD MPH, on behalf of the SOLID-TIMI 52 investigators European Society of Cardiology Congress

More information

Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford

Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford Oxford Technology Showcase 2016 Big Healthcare Challenges in chronic disease Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford Chronic diseases.. are long-term

More information

Keith A. A. Fox on behalf of the ROCKET AF Investigators

Keith A. A. Fox on behalf of the ROCKET AF Investigators Prevention of Stroke and non-cns Embolism with Compared with in Patients with Non-valvular Atrial Fibrillation and Moderate Renal Impairment Keith A. A. Fox on behalf of the ROCKET AF Investigators Disclosures

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE. Jonathan Poveda CLINICA BIBLICA 2015

TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE. Jonathan Poveda CLINICA BIBLICA 2015 TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE Jonathan Poveda CLINICA BIBLICA 2015 COURAGE First coronary angioplasty lesion (circles) two days before (A), immediately after (B), and one month after

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

EUROACTION. A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS

EUROACTION. A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS EUROACTION A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS Professor David Wood on behalf of the EUROACTION Group EUROACTION 8 countries 24 centres 962 subjects

More information

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,

More information

Models of preventive care in clinical practice to achieve 25 by 25

Models of preventive care in clinical practice to achieve 25 by 25 Models of preventive care in clinical practice to achieve 25 by 25 Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College

More information

Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil

Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil Defining Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD Brazil 1 Disclosure Honoraria received for consulting, speaker and or researcher activities : Astra Zeneca, Akcea, Amgen, Biolab, Esperion,

More information

No Increased Cardiovascular Risk for Lixisenatide in ELIXA

No Increased Cardiovascular Risk for Lixisenatide in ELIXA ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus

More information

Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial

Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods

More information

Members of The Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees

Members of The Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees Members of The Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees and of the Chinese Medicine Council of Hong Kong (e) (f) (g) a chairman;

More information

Descendants of Luigi Lobosco

Descendants of Luigi Lobosco Descendants of Luigi Lobosco Generation No. 1 1. Luigi 3 Lobosco (Michele 2, Rosario 1 ) was born September 02, 1895 in Sala Consilina, Italy, and died February 25, 1978 in Paterson, New He married Antonia

More information

PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona

PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker

More information

Statement and Return Report for Certification

Statement and Return Report for Certification Statement and Return Report for Certification - Representative in Congress 3th Congressional District Vote for Page of 9 Assembly District 68 3,36 3 66 3 4,43 Total Ballots 36,676 Total Applicable Ballots

More information

Lowering blood pressure (BP) in patients with type 2

Lowering blood pressure (BP) in patients with type 2 Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial William B. White, MD; Fatima Jalil, MD;

More information

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES 1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)

More information

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline

More information

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist Undetectable = Untransmittable Mariah Wilberg Communications Specialist Undetectable=Untransmittable PLWH who get and stay undetectable have effectively no risk of transmitting HIV to their sex partners

More information

DECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators

DECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators DECISION - CTO Drug-Eluting stent Implantation versus optimal Medical Treatment in patients with ChronIc Total OccluSION Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators Asan Medical

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

The 1 st Congress of Asian Society of Cardiovascular Imaging

The 1 st Congress of Asian Society of Cardiovascular Imaging The 1 st Congress of Asian Society of Cardiovascular Imaging April 27 (Friday) ~ April 28 (Saturday), 2007 Asan Medical Center, Seoul, Korea Number of Participants : 545 Participants from 26 Countries

More information

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,

More information

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV GUY DE BACKER Ghent University,Belgium ESC Congress 2012, aug.25-29th, Munich, Germany ESC Congress 2012, aug.25-29th, Munich,

More information

Main developments in past 24 hours

Main developments in past 24 hours ECDC DAILY UPDATE Pandemic (H1N1) 2009 Update 02 October 2009, 09:00 hours CEST Main developments in past 24 hours Weekly Influenza Surveillance Overview to be published today; Media highlights and Eurosurveillance

More information

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers

WELLNESS COACHING. Wellness & Personal Fitness Solution Providers WELLNESS COACHING Wellness & Personal Fitness Solution Providers Introducing Ourselves... We are Personal Wellness Coaches 2 We help people look and feel better by: - Educating on proper nutrition (80%)

More information

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:

More information

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating

More information

IMProved Reduction of Outcomes: Vytorin Efficacy International Trial

IMProved Reduction of Outcomes: Vytorin Efficacy International Trial IMProved Reduction of Outcomes: Vytorin Efficacy International Trial A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet)

More information

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David

More information

Appendix 5 Members of the Chinese Medicine Council of Hong. Kong, Chinese Medicine Practitioners Board, Chinese

Appendix 5 Members of the Chinese Medicine Council of Hong. Kong, Chinese Medicine Practitioners Board, Chinese Appendix 5 Members of the Chinese Medicine Council of Hong Kong, Chinese Medicine Practitioners Board, Chinese Medicines Board and its Committees and of the Chinese Medicine Council of Hong Kong a chairman;

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A

More information

Early discharge in selected patients after an acute coronary syndrome can it be safe?

Early discharge in selected patients after an acute coronary syndrome can it be safe? Early discharge in selected patients after an acute coronary syndrome can it be safe? Glória Abreu, Pedro Azevedo, Carina Arantes, Catarina Quina-Rodrigues, Sara Fonseca, Juliana Martins, Catarina Vieira,

More information

Statement and Return Report for Certification

Statement and Return Report for Certification Statement and Return Report for Certification General Election 3 - /5/3 - Member of the City Council st Council District Vote for Page of 8 /3/3 :3:8PM Assembly District 65 General Election 3 - /5/3 Member

More information